Haven't posted in years, but I'm a longtime lurker
Post# of 148154
(Total Views: 631)
Posted On: 01/24/2024 5:09:37 PM
Haven't posted in years, but I'm a longtime lurker and proud owner of a few thousand shares.
I recently came across an article that said cancer is now the leading cause of death for HIV-positive people. This caught my attention because the new trial being considered for leronlimab is apparently going to look at chronic immune activation and inflammation with respect to "strokes, heart attacks, and other vascular events," and Dr Lalezari noted at the time that these conditions "remain the leading cause of death in people living with HIV."
So--for the science-inclined posters out there (Ohm?)-- since leronlimab seems to work on cancer, should Cytodyn include cancer as an indication in the new protocol? Even as a secondary outcome?
This seems like a great opportunity, in a single trial, to establish the efficacy of leronlimab in cancer as well as vascular events, in HIV-positive patients. Of course we don't know the protocol for the proposed trial that is being negotiated... but there was no mention of cancer in the Cytodyn webcast. I am not a scientist or a medical researcher, but are there some good reasons that you wouldn't want to include an indication like cancer along with vascular events? Would it make the trial too complex, or are there different mechanisms of action that would to be hard to track in a single trial? Seems like to good of an opportunity to pass up, unless expanding the indications would mean a more expensive trial, and we all know Cytodyn is cash-poor... At least you would want to include all-cause mortality in the secondary outcomes, right?
The article I saw was in my Yahoo feed, but came from Melissa Rudy from Fox News--https://www.yahoo.com/news/cancer-now-leading-cause-death-103057869.html--The article relied on statistics from "Cancer Facts and Figures" from the American Cancer Society, and the most relevant indications included Hodgkins and non-Hodgkins lymphomas, Kaposi sarcoma, and cervical, liver, anal, and lung cancers.
Any insight would be appreciated. And I am two years removed from surgery and chemo for colon cancer (successful!), so I have a personal interest in leronlimab and cancer, above and beyond any money I might make on Cytodyn...
Well, I've enjoyed (most) of the comments and commentators on the message board, especially those dealing with science/medical issues. Its been a crazy ride, and I read you guys regularly, so thanks are in order. I didn't see any comments about this on the message board, so I thought I'd weigh in with this new info and a question. Thanks in advance for any responses!
I recently came across an article that said cancer is now the leading cause of death for HIV-positive people. This caught my attention because the new trial being considered for leronlimab is apparently going to look at chronic immune activation and inflammation with respect to "strokes, heart attacks, and other vascular events," and Dr Lalezari noted at the time that these conditions "remain the leading cause of death in people living with HIV."
So--for the science-inclined posters out there (Ohm?)-- since leronlimab seems to work on cancer, should Cytodyn include cancer as an indication in the new protocol? Even as a secondary outcome?
This seems like a great opportunity, in a single trial, to establish the efficacy of leronlimab in cancer as well as vascular events, in HIV-positive patients. Of course we don't know the protocol for the proposed trial that is being negotiated... but there was no mention of cancer in the Cytodyn webcast. I am not a scientist or a medical researcher, but are there some good reasons that you wouldn't want to include an indication like cancer along with vascular events? Would it make the trial too complex, or are there different mechanisms of action that would to be hard to track in a single trial? Seems like to good of an opportunity to pass up, unless expanding the indications would mean a more expensive trial, and we all know Cytodyn is cash-poor... At least you would want to include all-cause mortality in the secondary outcomes, right?
The article I saw was in my Yahoo feed, but came from Melissa Rudy from Fox News--https://www.yahoo.com/news/cancer-now-leading-cause-death-103057869.html--The article relied on statistics from "Cancer Facts and Figures" from the American Cancer Society, and the most relevant indications included Hodgkins and non-Hodgkins lymphomas, Kaposi sarcoma, and cervical, liver, anal, and lung cancers.
Any insight would be appreciated. And I am two years removed from surgery and chemo for colon cancer (successful!), so I have a personal interest in leronlimab and cancer, above and beyond any money I might make on Cytodyn...
Well, I've enjoyed (most) of the comments and commentators on the message board, especially those dealing with science/medical issues. Its been a crazy ride, and I read you guys regularly, so thanks are in order. I didn't see any comments about this on the message board, so I thought I'd weigh in with this new info and a question. Thanks in advance for any responses!
(16)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼